Press Releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
May 14, 2014Data underscore breadth of oncology portfolio
Eisai Inc. announced today that 10 abstracts highlighting new study results will be presented during the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO), taking place in...
- Apr 3, 2014- Company to Present Data on SF3B1 Program at a Symposium During the American Association for Cancer Research Annual Meeting 2014 -
H3 Biomedicine Inc., a biopharmaceutical company specializing in the discovery and development of precision medicines for oncology, announced today...
-
Mar 31, 2014
Eisai Inc., a subsidiary of Tokyo-based Eisai Co., Ltd., today announced the sale and assignment of its rights to a worldwide exclusive license...
-
Mar 13, 2014Sisters Network® Inc. launches innovative pilot program designed to help address breast cancer disparities affecting the African American community
Sisters Network, the only national African American breast cancer survivorship organization, announced today the launch of Teens 4...
-
Feb 27, 2014Patient Recruitment Now Underway at Treatment Centers Across the United States
Eisai Inc. today announced the start of a large, randomized Phase 3 trial to compare the efficacy, safety and tolerability of eribulin mesylate...
-
Feb 2, 2014
Eisai Inc. announced today that the Phase 3 SELECT trial (Study 303) of investigational agent lenvatinib met its primary endpoint. Compared to...
-
Dec 9, 2013Seeking indication for prevention of chemotherapy-induced nausea and vomiting
Helsinn Group and Eisai Inc. today announced that the U.S. Food and Drug Administration (FDA) accepted for review the...
-
Dec 4, 2013
Eisai Inc. announced today that five abstracts highlighting new study results will be presented during the 2013 San Antonio Breast Cancer...
-
Oct 9, 2013Cornucopia Cancer Support Center™ Joins Forces with the Eisai Women’s Oncology Program - Magnolia™, CancerCare®, Cancer Support Community(SM) and Meals On Wheels Association of America™ to Help Ease the Stress of Those Living with Breast Cancer
Woodcliff Lake, NJ, October 7, 2013- Magnolia Meals at HomeTM, a program that delivers nutritious meals at no-cost to patients living with breast cancer and their families, is now available in...
-
Oct 9, 2013
Morphotek®, Inc., a subsidiary of Eisai Inc., announced today that the Children's Oncology Group (COG) has opened enrollment in a Phase 1 clinical study...
-
Oct 1, 2013Eisai, CancerCare®, and Cancer Support Community(SM) Launch meal Trains(SM) sponsored by Magnolia™ During Breast Cancer Awareness Month; Campaign Aims to Drive 1,000 New meal Trains in October
Eisai Inc., along with collaborators CancerCare and Cancer Support Community, have announced meal TrainsSM sponsored by Magnolia™, which aim...
-
Sep 16, 2013- Companies Initiate Multiple Co-discovery Programs for First-in-class Targets in Oncology -
H3 Biomedicine Inc., a biopharmaceutical company specializing in the discovery and development of precision oncology...
-
Aug 8, 2013
Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to its investigational compound...
-
Jul 8, 2013The Eisai Women’s Oncology Program - MagnoliaTM, CancerCare®, Cancer Support CommunitySM and Meals On Wheels Association of AmericaTM Are Working Together to Help Ease the Stress of Those Living with Breast Cancer in New Jersey
Woodcliff Lake, NJ, July 8, 2013- Magnolia Meals at Home™, a program that delivers nutritious meals at no-cost to patients living with breast cancer and their families, is now available in Essex...
-
May 16, 2013
Eisai Inc. announced today that nine abstracts highlighting new study results in melanoma, breast and endometrial cancer will be presented during...
-
May 16, 2013Data to Be Presented at Annual Meeting of the American Society of Clinical Oncology (ASCO)
Helsinn Group and Eisai Inc. announced today top-line results from Helsinn's pivotal clinical studies investigating the...
-
May 9, 2013
Eisai USA Foundation Inc., the charitable arm of Eisai Inc., announces that it has pledged a $1 million donation to the Conquer Cancer Foundation...
-
Mar 21, 2013- Companies to Provide Open Access to Information with Goal of Accelerating Discovery of Medicines for People Living with Difficult-to-Treat Cancers -
H3 Biomedicine Inc., a biopharmaceutical company specializing in the discovery and development of oncology treatments, and BGI,...
-
Feb 21, 2013
Woodcliff Lake, NJ and Montreal, Quebec, February 21, 2013 - Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., and Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX)...
-
Feb 14, 2013
Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to its investigational drug...
-
Jan 10, 2013
Morphotek(®) Inc., a wholly-owned subsidiary of Eisai Inc., announced today top-line results from a Phase III study of its investigational agent...
-
Dec 19, 2012- Companies Pledge to Make Results Publicly Accessible in an Effort to Accelerate Cancer Drug Development -
H3 Biomedicine Inc., a biopharmaceutical company specializing in the discovery and development of oncology treatments, announced today that it has...
-
Dec 17, 2012
Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., today announced that it has entered into a definitive asset...
-
Dec 7, 2012
Results from the first large, global Phase III study of Halaven(®) (eribulin mesylate) Injection in patients with early-stage metastatic breast cancer...
-
Nov 28, 2012
Eisai Inc. announced today that six abstracts highlighting new study results will be presented during the 2012 CTRC-AACR San Antonio Breast...
